We are still marveling at the prowess of this creation, but something is happening underneath the surface. Our artificial assets affect our ability to act autonomously Read more
Forbes - Nov 22
TG Therapeutics (NASDAQ:TGTX – Free Report) had its price objective increased by JPMorgan Chase & Co. from $46.00 to $49.00 in a research report report published on Monday,Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock. Several other re... Read more
Defenseworld Net - Nov 04
